Zoetis Reports Strong 2025 Financials, Issues $3.85B in New Debt, and Repurchases $3.2B in Stock
ZTS is trading near its 52-week low of $115.25 (9.6% above the low) on elevated volume (2.1× avg).
Summary
Zoetis Inc. reported strong 2025 financial results with increased revenue and earnings, while significantly expanding its debt to fund share repurchases and general corporate purposes, alongside disclosing a material tax audit contingency.
Key Events · Earnings and Guidance · ZTS
-
Strong 2025 Financial Performance
Zoetis reported a 2% increase in total revenue to $9.47 billion, an 8% rise in net income to $2.67 billion, and a 10% increase in diluted EPS to $6.02 for the fiscal year ended December 31, 2025. This follows the preliminary results announced in a recent 8-K filing on 2026-02-12.
-
Significant Capital Market Activity
The company issued $2.0 billion in 0.250% convertible senior notes due 2029 and $1.85 billion in senior notes (4.150% due 2028 and 5.000% due 2035) in 2025, leading to a substantial increase in total long-term debt from $5.22 billion to $9.04 billion.
-
Substantial Share Repurchases
Zoetis repurchased 23.9 million shares for $3.2 billion in 2025. Notably, $1.78 billion of these repurchases were funded by the proceeds from the convertible senior notes offering, aiming to mitigate dilution.
-
Temporary International Revenue Boost
The International segment's Q4 2025 revenue saw a 2.5-3.5% increase due to accelerated sales timing related to fiscal year alignment, a non-recurring operational change that will not recur in future periods.
Analysis · ZTS · Life Sciences
Zoetis Inc.'s 2025 Annual Report details robust financial performance with significant growth in revenue, net income, and diluted EPS. The company undertook substantial capital market activities, including issuing $2.0 billion in convertible senior notes and $1.85 billion in senior notes, which significantly increased its long-term debt. A large portion of these proceeds, totaling $1.78 billion, was strategically used for share repurchases, aiming to offset potential dilution from the convertible notes and return capital to shareholders. Investors should note the temporary 2.5-3.5% boost to Q4 2025 international revenue due to accelerated sales timing related to fiscal year alignment, which is not expected to recur. Additionally, a material contingent liability of $450 million from an ongoing IRS tax audit presents a notable risk, although the company intends to contest the position.
At the time of this filing, ZTS was trading at $126.33 on NYSE in the Life Sciences sector, with a market capitalization of approximately $55.4B. The 52-week trading range was $115.25 to $177.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.